Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome

NCT04106557 is registered in ClinicalTrials.gov with Healx AI as lead sponsor.

NCT NCT04106557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04106557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome
Lead sponsor
Healx AI
Phase
Phase 3
Overall status
Completed
Start date
September 9, 2019
Completion date
November 2, 2020
Enrollment
104 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

primary disease or condition being studied: angelman syndrome (as)